3 findings behind this formula. Hover a card for the detail and the source.
Nattokinase lowered systolic and diastolic blood pressure compared with placebo across six randomised trials.
Meta-analysis of six RCTs with 546 participants: systolic pressure fell by about 3.5 mmHg and diastolic by 2.3 mmHg versus placebo. No notable adverse events were reported.
In adults with high-normal or stage 1 high blood pressure, nattokinase lowered systolic and diastolic pressure over eight weeks.
Randomised, double-blind, placebo-controlled trial in 86 adults aged 20-80 taking 2,000 FU nattokinase daily. Systolic pressure fell 5.55 mmHg and diastolic 2.84 mmHg more than placebo.
Taking nattokinase daily for two months lowered blood levels of the clotting proteins fibrinogen, factor VII and factor VIII.
Open-label clinical study in 45 adults (healthy, with cardiovascular risk factors or on dialysis) taking 4,000 FU a day. After two months fibrinogen fell 7-10%, factor VII 7-14% and factor VIII 17-19%, with no notable adverse events.